Wils J
Department of Oncology, Laurentius Hospital, Roermond, The Netherlands.
J Chemother. 2007 Apr;19(2):115-22. doi: 10.1179/joc.2007.19.2.115.
This manuscript summarizes recent progress in the adjuvant treatment of colon cancer. 5-Fluorouracil plus leucovorin, that have been considered standard therapy over the last 15 years, have now been replaced by combination chemotherapy, at least in stage III disease. The treatment of stage II disease is still somewhat less established. Prognostic and predictive biological markers are urgently needed for further fine-tuning of therapy. Molecular targeted agents have been developed with proven activity in advanced disease and are now being assessed in the adjuvant setting. It is expected that the inclusion of these new agents will lead to a further enhancement of treatment outcome. Those involved in the treatment of colorectal cancer should be encouraged to continue to provide optimal patient care and to participate in clinical trials in order to increase the evidence on which they can base their clinical judgement and to make further progress.
本手稿总结了结肠癌辅助治疗的近期进展。在过去15年里一直被视为标准疗法的5-氟尿嘧啶加亚叶酸，现在已被联合化疗所取代，至少在III期疾病中是如此。II期疾病的治疗仍不太明确。迫切需要预后和预测性生物标志物以进一步优化治疗。已开发出在晚期疾病中具有经证实活性的分子靶向药物，目前正在辅助治疗环境中进行评估。预计纳入这些新药物将进一步提高治疗效果。应鼓励参与结直肠癌治疗的人员继续提供最佳的患者护理并参与临床试验，以便增加他们可作为临床判断依据的证据并取得进一步进展。
